\
&
Contact us
\
&
Contact us
This was 3 years ago
LocationHybrid event
A recent study by European Parliament's Panel for the Future of Science and Technology (STOA) investigated the feasibility of creating a large-scale European public infrastructure aimed at addressing vulnerabilities linked to the research, development, production and distribution of medicines.
On this basis, STOA is organising a panel discussion which will bring together experts from biomedical research, representatives of the pharmaceutical industry, and EU and international public health experts. The aim is to discuss the state-of-play of the EU's current pharmaceutical strategy and explore policy options for strengthening EU preparedness and response, including the feasibility of creating an advanced EU pharmaceutical infrastructure for the research and development of novel medicines and treatments. The panel discussion will be moderated by Karin SIPIDO, Head of Experimental Cardiology at KU Leuven, and the panel includes representatives from the European Commission. You can follow remotely or you can join the debate live in Brussels.
More information, the detailed programme and registration is available on the event's webpage.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
